Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel (NCT02946788), a non-randomized phase 2 study. The primary outcome is Change From Baseline in Inflammatory Lesion Counts at Week 12.

2. Clinical Question

3. Trial Design

This was a completed phase 2 study with an open-label, non-randomized, parallel design. The registry lists enrollment of 20. It names BioPharmX, Inc. as sponsor and describes BPX-01 as minocycline topical gel at 1% and 2%. The study’s stated purpose was photo-documentation and collection of time-to-response data in moderate to severe inflammatory non-nodular acne vulgaris.

Open label means the registry does not describe masking of treatment assignment. Non-randomized allocation means participants were not assigned to study arms by a random process, according to the listed design. The record does not report the assignment procedure. As a result, the groups cannot be treated as interchangeable comparison groups: differences between them could reflect differences in who entered each arm as well as differences related to concentration. The record itself cautions against reading the arms as a like-for-like control comparison.

The listed study start was 2017-03-13 and primary completion was 2018-06-01; status is completed. The registry lists one outcome measure and no analyses. The primary endpoint is change from baseline in inflammatory lesion counts at week 12. Although the brief description also refers to time-to-response data and photographs, numerical time-to-response results and photo-based results are not reported in the registry record.

The registry record does not report the rationale for the enrollment target, a formal sample-size justification, the planned statistical tests, or a detailed schedule of assessments. The design supports describing what was recorded in each treatment group, but without randomization or a stated control arm it does not provide a randomized estimate of the causal effect of one concentration relative to the other or to no treatment.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: participants

6. Primary Endpoint

The registry lists the primary outcome as Change From Baseline in Inflammatory Lesion Counts at Week 12, measured over 12 weeks.

The primary endpoint is change from baseline in inflammatory lesion counts at week 12, measured in inflammatory lesions. The description defines it as the difference in the number of inflammatory lesions at week 12 compared with baseline. The record specifies a mean parameter and lists full range as the dispersion. It does not give the observed mean change, the range, or an analysis result.

Lesion counts provide a direct way to quantify the inflammatory lesions that the study sought to address. Measuring change from baseline focuses on how counts differ over the study period, rather than only describing the count at a single visit. The week 12 timeframe gives the endpoint a specified assessment point. These features make the measure interpretable as a descriptive summary of change within the study groups, if the underlying results are available.

The registry record does not report how baseline values were summarized, whether the change was calculated for each participant before averaging, how missing week 12 observations were handled, or whether any adjustment was planned. It also does not report confidence intervals or a test of the endpoint. Without those results and methods, the endpoint definition alone cannot indicate the size, variability, or precision of the observed change. The stated mean and full-range dispersion describe the intended summary, not a numerical finding.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a phase 2, parallel study with open-label treatment and non-randomized allocation. These terms characterize the design; they do not specify the statistical analysis. The record lists one primary outcome measure and no analyses. Details of the analysis plan, statistical tests, model, covariate adjustment, and uncertainty estimates are not reported in the registry record.

What does non-randomized allocation imply?

In a randomized study, chance assignment is used to make treatment groups comparable on average at the start, including for characteristics that may not have been measured. Non-randomized allocation does not provide that protection. If participant characteristics or treatment selection differed between the BPX-01 1% and 2% groups, those differences could affect endpoint outcomes. This is why a difference between group summaries cannot automatically be attributed to concentration. The record does not say how allocation was decided or whether any methods were used to account for group differences.

What does open label mean for measurement?

Open label means treatment assignment was not masked as described in the registry. Knowledge of treatment can influence participant reports, clinical decisions, or outcome assessment in some settings. The primary endpoint is a count of inflammatory lesions, but the record does not describe who assessed the lesions, whether assessors were independent, or whether photographs were rated using a specified procedure. Those measurement details are not reported in the registry record. The mention of photo-documentation describes an aim, not the results or safeguards used to measure lesions.

How should a change-from-baseline mean be understood?

A change score represents the difference between a participant’s measurement at follow-up and their baseline measurement, under the direction convention used by the study. A group mean summarizes individual changes. The registered endpoint specifies a mean and a week 12 timeframe, but no numerical result or direction convention is reported. The registry description says the endpoint is the difference in lesion count at week 12 compared with baseline; it does not give the values needed to interpret the size or direction of the group mean.

Full range is a descriptive measure of spread, identifying the lowest and highest observations in the summarized data. In general, a range can be strongly influenced by extreme observations and does not by itself describe the typical amount of variation for most participants. Here, the record names full range but does not report its endpoints or clarify the exact observations over which it was calculated. A range also does not replace an uncertainty interval for the mean.

What can a confidence interval or p-value add?

In general, a confidence interval communicates the precision of an estimated quantity under a specified statistical procedure. A narrow interval indicates greater precision than a wide interval, while neither interval alone establishes that a result is clinically important. A p-value evaluates how compatible the data are with a null hypothesis under the assumptions of a specified test; it is not the probability that a treatment works. The registry record reports neither a confidence interval nor a p-value, and it does not state which test or estimation method was planned.

It is also not reported whether the endpoint analysis would compare each group with its own baseline, contrast the groups, or use another approach. No regression model, repeated-measures method, baseline adjustment, or handling of distributional assumptions is specified. No such method should be inferred from the endpoint description alone.

What are planning illustrations?

In general, a sample-size calculation estimates how many participants may be needed for a design to have a stated chance of detecting an effect under chosen assumptions. The planning assumptions described for this study use a two-sided significance level of 0.05, equal allocation, a normal approximation, and effects defined as fractions of the observed effect. They are planning illustrations based on the observed effect, not the trial’s own design. The record does not report a trial-specific sample-size justification. Such illustrations are not observed power and do not indicate how likely the result is to be true. They also cannot replace an estimate and uncertainty interval for the endpoint.

Because the registry does not report the endpoint values or analysis output, no recalculated estimate can be made from the posted record. In general, recalculations from summary statistics are unadjusted and may not reproduce a sponsor’s analysis; the record does not provide a sponsor analysis to compare with. Interpretation is therefore limited to the registered design and outcome definitions, rather than inferential conclusions.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists one primary outcome measure and no analyses. It does not report a statistical analysis plan, a hierarchy of endpoints, or a strategy for handling multiple statistical tests. It is therefore not possible to determine whether the study planned formal hypothesis testing or how any multiplicity would have been addressed. The other stated aims, including photo-documentation and time-to-response information, do not have numerical results reported in the registry record.

Missing-data handling is also not reported in the registry record. The enrollment is listed as 20, while the safety entries list 8 participants at risk in the BPX-01 1% group and 10 in the BPX-01 2% group. These figures are safety denominators; the registry does not explain the difference between those entries and total enrollment or provide participant flow, endpoint-specific denominators, or reasons for any unavailable observations. It would be inappropriate to infer withdrawals or missing endpoint values from these figures.

The record does not state whether the primary endpoint analysis used all enrolled participants, participants who received treatment, participants with baseline and week 12 measurements, or another population. It also does not describe imputation, exclusion rules, or sensitivity analyses. In general, missing-data choices can affect estimates when the availability of measurements is related to participant outcomes or treatment experience. Without the analysis population and missing-data methods, the representativeness of any endpoint estimate cannot be assessed. No numerical primary result is posted to evaluate in any case.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The registry reports safety counts separately for the BPX-01 1% and BPX-01 2% groups. Serious adverse events affected 0 of 8 participants at risk in the 1% group and 0 of 10 at risk in the 2% group. Deaths were reported as 0 in each group. Other adverse events affected 2 of 8 participants at risk in the 1% group and 3 of 10 at risk in the 2% group.

These are counts, not comparative estimates. Because allocation was non-randomized and the groups are not a like-for-like control comparison, the entries do not establish that one concentration is safer than the other. Zero reported serious events does not establish that serious events cannot occur; the listed groups are limited in size, and the record does not give event-level detail. Serious adverse event terms are not listed. The registry record also does not report the specific other adverse events, their severity, timing, duration, or relationship to treatment. The counts should therefore be read as a limited description of events recorded for the listed safety groups, not as a complete safety profile.

12. What the Result Does, and Does Not, Mean

The record identifies a study of BPX-01 minocycline topical gel at 1% and 2% in moderate to severe inflammatory non-nodular acne vulgaris. It specifies a primary endpoint based on change in inflammatory lesion counts at week 12 and reports an open-label, non-randomized, parallel design. Those details establish what the study intended to examine, but the registry record does not report a numerical result for the primary endpoint.

Without the endpoint estimate and its uncertainty, the posted information cannot show the magnitude or precision of change. It cannot establish whether the mean count changed, how variable participant outcomes were, or how the groups compared on the primary measure. The registry also does not report numerical photo-documentation findings or time-to-response results, despite these being part of the stated study purpose.

The two concentration groups do not constitute a randomized comparison. The record cautions that they are not a like-for-like control comparison, and does not report how participants were assigned. Any difference between groups, if obtained from another source, would need to be interpreted in light of possible differences between participants and the unmasked design. The record does not provide a basis for attributing a contrast solely to concentration.

The safety entries describe reported counts in the listed groups, including zero serious adverse events and zero deaths. They do not show that risk is absent, and they do not permit a robust comparative safety conclusion. In general, study findings apply most directly to the people and procedures represented in the study; the registry does not report enough participant characteristics to assess how closely this enrollment matches other populations.

Accordingly, the registry record supports a description of the research question and design, but not a conclusion about the size, precision, or comparative meaning of the primary outcome. The intended question should be distinguished from a demonstrated statistical result: numerical outcome estimates and analysis details are not reported in the registry record.

13. Why This Trial Matters Statistically

This study raises several central issues in interpreting clinical research: the distinction between a defined endpoint and a posted result, the consequences of non-randomized allocation, and the importance of reporting uncertainty and analysis methods. The registry clearly identifies change in inflammatory lesion counts at week 12 as the primary endpoint. However, without a numerical estimate, the endpoint definition cannot answer how much counts changed or how precisely that change was measured.

The non-randomized design is especially important when considering the two concentrations. In general, random assignment helps guard against systematic differences between groups, whereas non-randomized allocation can leave group differences entangled with the treatment contrast. The registry itself warns that these arms are not a like-for-like control comparison. This makes design context essential: a simple comparison of group outcomes, even if available elsewhere, would not carry the same interpretation as a randomized head-to-head estimate.

The study also illustrates why an endpoint’s summary format matters. A mean describes an average, while a full range gives the extremes of the observations. Neither alone communicates the precision of an estimate, and the record does not report the numerical summaries or uncertainty intervals. Statistical interpretation requires both an outcome estimate and enough methodological information to understand how it was obtained.

Finally, reporting the analysis population, missing-data approach, and planned tests is important for judging whether a result is robust and how it should be interpreted. These details are not reported in the registry record. The study’s enrollment and safety entries offer context, but they do not replace endpoint results or a documented analysis. The main statistical lesson is to separate what the design intended to measure from what the posted record actually establishes.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations arise directly from the registry information. First, the primary endpoint has no numerical result posted, and the record lists no analyses. The mean change and full range are therefore unavailable, as are confidence intervals, p-values, or other measures of uncertainty. This prevents assessment of both the observed magnitude and its precision.

Second, allocation was non-randomized and treatment was open label. The registry does not report the assignment procedure or masking of outcome assessors. Differences between the concentration groups may reflect participant or measurement differences as well as treatment concentration. The registry explicitly cautions that the arms are not a like-for-like control comparison.

Third, the registry does not provide participant characteristics, detailed eligibility criteria, participant flow, endpoint-specific denominators, or the analysis population. Enrollment is listed as 20, while safety denominators are 8 and 10; the reason for this difference is not reported in the registry record. No conclusion about endpoint completion or attrition should be inferred from the safety entries.

Fourth, methods for handling missing data, baseline adjustment, multiplicity, and statistical testing are not reported. The protocol’s sample-size justification is not reported in the registry record. The listed planning assumptions are illustrations based on the observed effect, not a description of the trial’s own design, and cannot establish observed power or remedy the absence of outcome results.

Finally, the study’s stated photo-documentation and time-to-response aims have no numerical results posted. Adverse-event detail is limited to group counts, with no serious event terms listed and no descriptions of other events. These gaps restrict interpretation of both efficacy-related outcomes and safety. The registry record does not provide enough information for a complete assessment of outcome measurement, analysis choices, or the broader applicability of any findings.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel — NCT02946788.
• Registry record last updated 2022-07-26; status last verified 2022-07.
• Results first posted 2022-07-26.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT02946788 is a completed phase 2, open-label, non-randomized parallel study sponsored by BioPharmX, Inc. It evaluated BPX-01 minocycline topical gel at 1% and 2% for moderate to severe inflammatory non-nodular acne vulgaris. Enrollment is listed as 20, with a study start of 2017-03-13 and primary completion on 2018-06-01.

The primary endpoint was change from baseline in inflammatory lesion counts at week 12, with the mean specified as the parameter and full range as dispersion. The registry lists one outcome measure and no analyses. It does not report a numerical primary endpoint result, confidence interval, p-value, analysis population, or missing-data method. The record cautions that the non-randomized arms are not a like-for-like control comparison.

Safety entries list 0 serious adverse events and 0 deaths in each group; other adverse events affected 2 of 8 at risk in the 1% group and 3 of 10 at risk in the 2% group. Further event details are not reported in the registry record.